In the News

Congratulations to Nexcelom Bioscience!



Riverwalk tenant, Nexcelom Bioscience, develops tools for cellular analysis and just announced that they received a strategic investment from Ampersand Capital Partners to support their growth and continue to help scientists advance in this field.

A leading provider of cell counting and analysis products for biomedical research and the biopharma industry, Nexcelom Bioscience is a fast-growing supplier of innovative instruments and software. Their platforms are used across a broad range of research fields including immuno-oncology, cell therapy, drug discovery, vaccine development and manufacturing, and therapeutic cell line generation.

At work in one of our customizable spaces, Nexcelom Bioscience is a member of our growing community of medical device and healthcare companies found here at Riverwalk.

Read the full press release announcing this new investment here.